Search Results

• • 5 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

  Authors:Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, et al.From:The Lancet (Vol. 398, Issue 10295) Peer-Reviewed

  July 10, 2021610 words Article

   Abstract Only

• Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

  Authors:Alberto M Borobia, Antonio J Carcas, Mayte Pérez-Olmeda, Luis Castaño, María Jesús Bertran, Javier García-Pérez, et al.From:The Lancet (Vol. 398, Issue 10295) Peer-Reviewed

  July 10, 20211,136 words Report

   Abstract Only

• Contemporary radiotherapy: present and future.

  Authors:Ravi A Chandra, Florence K Keane, Francine E M Voncken, and Charles R Thomas, Jr.From:The Lancet (Vol. 398, Issue 10295) Peer-Reviewed

  July 10, 2021191 words Brief article

   Abstract Only

• Histiocytosis.

  Authors:Jean-François Emile, Fleur Cohen-Aubart, Matthew Collin, Sylvie Fraitag, Ahmed Idbaih, Omar Abdel-Wahab, et al.From:The Lancet (Vol. 398, Issue 10295) Peer-Reviewed

  July 10, 2021355 words Brief article

   Abstract Only

• Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.

  Authors:Christopher Sweeney, Sergio Bracarda, Cora N Sternberg, Kim N Chi, David Olmos, Shahneen Sandhu, et al.From:The Lancet (Vol. 398, Issue 10295) Peer-Reviewed

  July 10, 2021949 words Article

   Abstract Only